VIBRIO ALGINOLYTICUS COLLAGENASE

DRUG2 trials

Sponsors

Fidia Farmaceutici S.p.A.

Conditions

Dupuytren contracturePeyronie’s Disease

Phase 1

A Phase I/II study of Vibrio alginolyticus collagenase in patients with Dupuytren contracture. A Phase I single ascending dose with a Phase II expansion, safety, tolerability, efficacy, pharmacokinetics and immunogenicity study

RecruitingCTIS2023-507332-20-00

Fidia Farmaceutici S.p.A.Dupuytren contracture

Start: 2024-12-18Target: 83Updated: 2026-01-23

A Phase I/II safety and efficacy study of Vibrio alginolyticus collagenase in patients with Peyronie’s Disease A Phase I single ascending dose with a Phase II expansion, safety, tolerability, efficacy, pharmacokinetics and immunogenicity study

RecruitingCTIS2023-509621-45-00

Fidia Farmaceutici S.p.A.Peyronie’s Disease

Start: 2025-04-22Target: 100Updated: 2025-04-30